CD79A and infection: This limitation primarily stems from the inability of intramuscular vaccines to induce mucosal immune responses in the upper respiratory tract, particularly antigen-specific IgA antibody responses, which are critical for blocking viral entry, replication, and transmission in mucosal epithelial cells during early infection (7, 8).